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Background: The Be The Match Registry provides
access to over 230,000 CBU with a median pre-freeze
Total Nucleated Cell (TNC) count of 105 x 10^7 TNC.
Prior studies have established an acceptable dose
threshold of at least 2.5 x 10^7 for the treatment of
hematological malignancies. Pediatric patients often only
require a single CBU to achieve suitable cell dose for
transplant (Tx) and some have received cell doses per
patient weight in excess of 20 x 10^7 TNC/kg. Mean-
while adults may require multiple units to achieve the
recommended minimal dose. This study evaluated
whether CBU Tx in peds achieving a cell dose >20 x
10^7 TNC/kg deplete a unit that may be suitable for an
adult patient when another potentially acceptable unit is
available for the child.
Methods: We identiﬁed 74 single CBU Tx of patients age
0-12 years old, facilitated through the Be The Match
Registry from Sept 2009 to Aug 2012 with a Tx cell dose
>20 x 10^7 TNC/kg. The CBU searches were reviewed to
determine whether another suitable CBU (10-20 x 10^7
TNC/kg and equivalent or better low resolution HLA-A, B,
C, high resolution -DRB1) was available for that patient. A
TNC threshold for CBU suitability for a potential adult
patient of 178 x 10^7 was established based on the
historical median weight of 71kg for adult CBU Tx
recipients.
Results: Of the 74 Tx evaluated, 58 (78%) units had
a minimum TNC of 178 x 10^7 (range 178-452), large enough
for the median weight adult patient. In 48 of the 58 cases
a suitable CBUwith 10-20 TNC/kgwas available on the search
with an equivalent or better HLA match and 23% of the time
the lower TNC CBU was a better HLA match. If the lower TNC
CBUs had been selected for this cohort, the median cell dose
would decrease from 28.7 to 11.5 TNC/kg.
Conclusions: The number of CBU in the registry that
meet the median adult patient dose of 178 x 10^7 TNC is
16,494 (7%) CBU compared to 234,292 available for peds
Tx. Transplant practice is often to take the largest CBU
available for a patient, with consideration of HLA match
differing between centers. This study shows that CBU
used in Tx for children can exceed 20 x 10^7 TNC/kg.
These CBU have a large TNC and could be suitable for
adolescent or adult single cord transplantation. Although
74 CBU Tx correspond to a small proportion of total peds
(age 12 and under) single CBU Tx during this timeframe
(n¼951), these units may offer the only opportunity for
an adult patient. With a limited number of CBUs
achieving high TNC available for adult patients, consid-
eration of the ethics of providing a young patient with an
adequate TNC CBU (e.g. 10-20 x 10^7 TNC/kg) vs the
largest TNC CBU will continue to confront the commu-
nity. Centers should consider selecting a CBU with
smaller, yet still substantial cell dose, particularly when
it's a better HLA match. Future outcomes research is
needed to elucidate the optimal TNC or identify
a maximum threshold recommendation for guidance in
CBU Tx in small children prior to a policy being imple-
mented.352
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Hematopoietic stem cell transplantation (HSCT) is
increasingly being used in the management of patients
with sickle cell disease (SCD). Although cure remains the
fundamental goal, preservation of fertility in this young
patient population is an important consideration. While it
is known that standard busulfan-based myeloablative
conditioning uniformly causes permanent gonadal
dysfunction, complete graft rejection is a serious drawback
in busulfan-free exclusively immunosuppressive-based
preparative regimens with ﬂudarabine and cyclophospha-
mide alone. Therefore if busulfan is to remain a central
part of the conditioning, a signiﬁcant dose reduction may
be necessary to cure and yet preserve fertility. The subse-
quent successful outcome and preservation of fertility in
two young adults transplanted in our center with
busulfan-based targeted-dose reduced intensity condi-
tioning (RIC) for paroxysmal nocturnal hemoglobinuria,
prompted us to consider this regimen in SCD. Between
September 2008 and April 2012, 16 patients with SCD
underwent HSCT in the Sultan Qaboos University Hospital,
Oman. The conditioning regimen consisted of ﬂudarabine
30mg/m2/day for 6 days, two days of targeted-dose
intravenous busulfan (target Css 850ng/ml) and rabbit anti-
thymocyte globulin (10mg/kg/day for 4 days beginning on
day minus 4). The median age was 18 yrs (range 9-40 yrs)
and transplant indications were recurrent vaso-occlusive
crises, acute chest syndrome and cerebrovascular events.
There were nine males and seven female patients. The
stem cell source was peripheral blood in 14 (88%) and bone
marrow in 2 patients (12%). Fourteen patients (88%) are
considered cured with a median follow up of 24 months
(6-49 mths). Nine (64%) of these patients have complete
donor chimerism (DC) while ﬁve (36%) patients have stable
mixed chimerism ranging from 67-90%. Two patients (12%)
rejected their grafts with rapid loss of DC by 6 months and
are alive with their original SCA manifestations. Acute graft
versus host disease (Grade III) occurred in only one patient
and resolved with therapy. Of the 6 post pubertal female
patients, only one has resumed normal periods following
the transplant. The ﬁve others (median age 24yrs, range
16-27yrs) developed amenorrhea post transplant with high
FSH and LH levels and have been started on hormonal
replacement therapy. No tests of gonadal function in the
male patients are available. Busulfan-based RIC HSCT is
curative and appears to be safe even in older patients with
SCA but gonadal damage continues to remain a long term
complication. There may be a window of opportunity to
further reduce busulfan exposure in an attempt to preserve
